Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) Research & Development (2016 - 2025)

Avanos Medical's Research & Development history spans 12 years, with the latest figure at $7.2 million for Q3 2024.

  • For Q3 2024, Research & Development rose 18.03% year-over-year to $7.2 million; the TTM value through Sep 2024 reached $27.3 million, up 2.25%, while the annual FY2023 figure was $27.2 million, 6.85% down from the prior year.
  • Research & Development for Q3 2024 was $7.2 million at Avanos Medical, up from $6.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $9.6 million in Q4 2020 and bottomed at $5.9 million in Q4 2021.
  • The 5-year median for Research & Development is $7.5 million (2023), against an average of $7.5 million.
  • The largest annual shift saw Research & Development tumbled 38.54% in 2021 before it grew 18.03% in 2024.
  • A 5-year view of Research & Development shows it stood at $9.6 million in 2020, then tumbled by 38.54% to $5.9 million in 2021, then grew by 6.78% to $6.3 million in 2022, then increased by 7.94% to $6.8 million in 2023, then grew by 5.88% to $7.2 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Research & Development are $7.2 million (Q3 2024), $6.3 million (Q2 2024), and $7.0 million (Q1 2024).